The United States FDA approves three doses of COVID-19 vaccine for immunocompromised persons

It is announced that The United States Food and Drug Administration (FDA) approved the third dose of COVID-19 vaccine for immunocompromised persons on August 12.

In a statement, FDA Interim Commissioner Janet Woodcock said “The next COVID-19 epidemic in the United States is on the rise. The FDA considers immunocompromised persons to be especially at risk for serious illness.”

After reviewing the data, the FDA approved a third dose of Pfizer-BioNTech or Moderna vaccine in small groups and it was decided that it could benefit vulnerable groups, the interim Commissioner Woodcock also added. Photo Source https://bit.ly/3jZwrxy

He said, “The Food and Drug Administration (FDA) is actively working with our partners on a science-based detailed process to determine whether a vaccine is needed in the future.”

According to the Centers for Disease Control and Prevention, an estimated 2.7 percent of adults in the United States are immunocompromised, including people who have undergone organ transplants, cancer patients, and people living with HIV.

Source (Xinhua)